Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nutritional status and drug resistance in EGFR-mutant NSCLC: a retrospective cohort study on almonertinib efficacy.

Naunyn-Schmiedeberg's archives of pharmacology - 1 Feb 2026

Wu Chao, Li Ying, Chen Shuxing, Wang Liuning, Chen Bangjie, Zhang Fenglin, Zhang Ziran, Zhang Congjun

Abstract excerpt

To evaluate the clinical efficacy and safety of Almonertinib in EGFR-mutant advanced NSCLC patients with different nutritional statuses. Clinical data from 56 patients with advanced EGFR-mutant NSCLC admitted to the First Affiliated Hospital of Anhui Medical University from April 2021 to April 2023 were retrospectively analyzed. Patients were stratified into two groups based on nutritional risk (nutritional risk...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Malnutrition

Share to Nutritional Status

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 41045332
DOI: 10.1007/s00210-025-04555-4

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nutritional status and drug resistance in EGFR-mutant NSCLC: a retrospective cohort study on almonertinib efficacy.PMID 41045332Read ↗

Efficacy and safety of anlotinib plus EGFR-TKI for advanced non-small cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Clinical analysis of anlotinib as first-line treatment for elderly patients with advanced lung adenocarcinoma without driver gene mutations.Semantic proximity Read ↗

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.Semantic proximity Read ↗

Characterization of pretreatment cachexia through cytokine and nutritional analysis in lung cancer: the Marató cohortSemantic proximity Read ↗

Association between frailty and chemotherapy toxicity in patients with gastrointestinal tumors: A prospective observational studySemantic proximity Read ↗

EGFR Mutation Subtypes Modulate Distinct Metabolic Profiles and Clinical Outcomes in Lung Cancer: A Retrospective AnalysisSemantic proximity Read ↗

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI.Semantic proximity Read ↗

Role of metabolic reprogramming in drug resistance to epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Baseline anemia predicts a poor prognosis in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: a retrospective study.Semantic proximity Read ↗

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma.Semantic proximity Read ↗

High Body Mass Index Was Related to Favorable Therapeutic Efficacy of Epidermal Growth Factor Receptor Targeted Therapy in Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.